









Atlas Genet Cytogenet Oncol Haematol. 2008;12(3)  197 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology                         
                         OPEN ACCESS JOURNAL AT INIST-CNRS 
BRCA1 (breast cancer 1, early onset) 
Sreeparna Banerjee 
Department of Biology, Middle East Technical University, Ankara 06531, Turkey 
Published in Atlas Database: October 2007 
Online updated version: http://AtlasGeneticsOncology.org/Genes/BRCA1ID163ch17q21.html  
DOI: 10.4267/2042/38518 
This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. 




Other names: BRCAI; BRCC1; IRIS; PSCP; RNF53 
Location: 17q21.31 
Local order: According to NCBI Map Viewer, genes 
flanking BRCA1 in centromere to telomere direction 
on 17q21 are: VAT1 17q21 (vesicle amine transport 
protein 1 homolog (T californica)); RND2 17q21 Rho 
family GTPase 2; RPL21P4 17q21 ribosomal protein 
L21 pseudogene 4; BRCA1 17q21 breast cancer 1, 
early onset; NBR2 17q21 neighbour of BRCA1 gene; 
BRCA1P1 17q21 BRCA1 pseudogene 1; NBR1 
17q21.31 neighbour of BRCA1 gene. 
Note: BRCA1 is a tumour suppressor phosphoprotein 
that combines with other tumour suppressors, DNA 
damage and repair proteins, and signal transducers to 
form a large multi-subunit protein complex known as 
BRCA1-associated genome surveillance complex 
(BASC). Truncating mutations and missence mutations 
in the BRCA1 gene are found in a large number of 
familial breast cancer cases. Individuals who inherit a 
germline mutation of BRCA1 or BRCA2 have a 
significantly increased lifetime risk for the 
development of breast and/or ovarian cancer. 
DNA/RNA 
Note: The subcellular localization and physiological 
function of this gene is greatly modulated by the 
several alternately splices isoforms that are found. 
Several of these alternatively spliced transcript variants 
have been described, however, not all have had their
full-length natures identified. 
Description 
According to Entrez-Gene, BRCA1 gene maps to 
NC_000017.9 in the region between 38449840 and 
38530994 on the minus strand and spans across 81.1 
kilo bases. According to Spidey (mRNA to genomic 
sequence alignment tool, 
http://www.ncbi.nlm.nih.gov/spidey), BRCA1 has 24 
exons, the sizes being 181, 99, 54, 78, 89, 140, 105, 47, 
77, 89, 172, 127, 191, 311, 88, 78, 41, 84, 55, 74, 61, 
1506. 
Transcription 
BRCA1 mRNA NM_007302.3 has 7388 bps. The 
BRCA1 gene contains two separate promoters that 
induce transcription of mRNAs with different 5'UTRs, 
a shorter 5'UTRa and a longer 5'UTRb. The 
downregulation of BRCA1 gene expression in certain 
breast cancers is caused by a switch from expression of 
a 5'UTRa, which enables efficient translation, to 
expression of 5'UTRb, which contains secondary 
structure and upstream open reading frames that 
strongly inhibit translation. 
Pseudogene 
According to Entrez Gene the BRCA1 pseudogene 1 
(BRCA1P1) is located on 17q21. 
Protein 
Note: BRCA1 sequence is not well conserved between 
mammals, however, two domains, the C terminal 
BRCT (BRCA1 C Terminal) motifs and the N-terminal 
RING domain are highly conserved. 
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The BRCA1 protein showing the RING finger domain, the Nuclear Localisation Signal domain and the BRCT domains. AA- amino acids. 
Description 
BRCA1 is an 1863 amino acid 220kDa protein with an 
E3 ubiquitin ligase activity as well as a phospho-
peptide binding activity. It has several domains that are 
essential for its function as depicted in the figure. The 
RING finger domain of BRCA1, commonly found in 
many DNA repair proteins, consists of a conserved 
core of approximately 50 amino acids in a pattern of 
seven cysteine residues and one histidine residue to 
form a structure that can bind to two Zn++ ions. This 
motif aids in mediating protein-protein interaction, as 
exemplified by the interaction of BRCA1 with BARD1 
(BRCA1 associated RING domain). This interaction is 
critical since mutations in the Zn++ binding regions, 
crucial for heterodimerization with BARD1, have been 
found in tumours. BRCA1 accumulates in distinct foci 
in the nucleus during S phase and this transfer is aided 
by its Nuclear Localisation Signal (NLS) domain. A 
further role of BARD1 is also implicated whereby its
association with the RING finger domain of BRCA1 is 
necessary for the transfer of BRCA1 to the nucleus. 
BRCA1 interacts with Rad50 of the MRN complex 
through the region AA 341-748 and can directly bind to 
branched, flap and four way DNA structures through a 
central domain spanning residues 452-1079. The 
protein inhibits the nucleolytic activities of the 
Mre11/Rad50/Nbs1 complex as a result of this direct 
DNA binding. The C terminus of BRCA1, which can 
function as a transcriptional activation domain, consists 
of two tandemly arranged elements called BRCT 
(BRCA1 C- terminal). This motif specifically binds to
phosphorylated proteins, an event that is commonly 
associated with DNA damage response. BRCA1 is 
capable of interacting directly with BRCA2 and with 
Rad51 via BRCA2 through this motif. Another protein 
that interacts with BRCA1 via BRCT is the BRCA1 
associated C-terminal helicase (BACH1). BACH1 is 
said to aid BRCA1 in the DNA damage response and 
maintain the protein at the nuclear foci formed after 
DNA damage response. Other proteins that can interact 
with BRCA1 through the BRCT domains are C 
terminal Interacting protein /CtIP), RNA Polymerase II, 
BACH 1 (a member of DEAH helicase family) and 
p53. 
Expression 
BRCA1 is ubiquitously expressed in humans with the 
highest levels observed in the ovaries, testis and 
thymus. It is a tumour suppressor and a reduced 
expression is correlated with the transformation 
procedure and aetiology of sporadic breast cancer. This 
reduction is expression is said to be transcriptionally 
regulated with implications of aberrant promoter 
methylation at CpG dinucleotides as well as CREB 
binding sites. 
Localisation 
Located in the nucleus. 
Function 
Role of BRCA1 in DNA repair: BRCA1 is a part of a 
large complex of proteins, the BASC, which monitors 
the genome for damage and signals downstream 
effectors. BRCA1 has been implicated in two pathways 
of DNA double strand break repair: homologous 
recombination (HR) and non homologous end joining 
(NHEJ). Upon exposure to DNA damaging agents, 
BRCA1 becomes hyperphosphorylated and is rapidly 
relocated, along with Rad51, to sites of DNA synthesis 
marked by proliferating cell nuclear antigen (PCNA). 
Rad51, a homolog of the bacterial RecA, is a central 
player in HR, catalyzing the invasion of the single 
stranded DNA in a homologous duplex and facilitating 
the homology search during the establishment of joint 
molecules. A recent study, however, has indicated that 
BRCA1 deficient breast cancer cells compensate for 
this deficiency by upregulating Rad51. The resultant 
HR may be erroneous and thereby lead to 
tumorigenesis. In addition, BRCA1 is said to inhibit the 
MRN complex which is is implicated in bringing 
together two DNA strands together for the error prone 
NHEJ. BRCA1-deficient cells are sensitive to ionizig 
radiation and DNA damaging drugs, such as mitomycin 
C. 
Transcriptional regulation: BRCA1 is capable of 
transcriptional regulation and chromatin remodelling 
when tethered to promoters of genes important in the 
DNA repair process and breast cancer markers. It is a  
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member of the core RNA polymerase II transcriptional 
machinery, a feature exploited by the DNA damage 
recognition process. In addition, BRCA1 interacts with 
p300/CBP, transcriptional coactivators for CREB. 
p300/CBP are inhibited by the viral oncoprotein E1A 
and the functionality of E1A as an oncogene could be 
in part caused by an obstruction of BRCA1:p300/CBP 
cooperation resulting in the loss of the tumour-
suppressing function of BRCA1. BRCA1 can act as a 
transcriptional coactivator or co repressor of proteins 
implicated in chromatin remodelling, such as the 
histone deacetylase complexes or components of the 
SWI/SNF-related chromatin-remodelling complex. 
Cell Cycle Regulation by BRCA1: BRCA1, based on 
its phosphorylation status, elicits DNA damage induced 
cell cycle arrest at several stages through modulation of 
specific downstream target genes. BRCA1 
transactivates p21cip1/WAF1, which contributes to an 
arrest at the G1/S boundary. ATM phosphorylation of 
BRCA1 appears to be important for its role in the intra 
S phase checkpoint activation. BRCA1 is also 
implicated in the transcriptional regulation of several 
genes such as cyclinB, 14-3-3sigma, GADD45, wee-1 
kinase and PLK1 associated with the G2/M checkpoint. 
p53-dependent apoptosis: The BRCA1 protein is 
capable of physically interacting with the p53 tumour 
suppressor gene, and can stimulate p53-dependent 
transcription from the p21WAF1/CIP1 mdm2 and 
promoters. In addition, the BRCA1-BARD1 complex is 
required for the phosphorylation of p53 at Ser15 by 
ATM/ATR following DNA damage by IR or UV 
radiation. The phosphorylation of p53 at Ser-15 is 
essential for the G(1)/S cell cycle arrest via 
transcriptional induction of the cyclin-dependent kinase 
inhibitor p21 after DNA damage. 
Ubiquitination: BRCA1 and BARD1 interact together 
to form an E3 ubiquitin ligase. RNA polII stalled at
sites of DNA damage is a target for this ubiquitin ligase 
mediated degradation following DNA damage, thereby 
allowing access to the repair machinery. BRCA1 
ubiquitinates the transcriptional preinitiation complex, 
not for proteasomal degradation, but to prevent a stable 
association of TFIIE and TFIIH; thereby blocking the 
initiation of mRNA synthesis. 
Homology 
Dog (Canis familiaris): BRCA1; 
Chimpanzee (Pan troglodytes): BRCA1; 
Rat (Rattus norvegicus): Brca1; 
Mouse (Mus musculus): Brca1; 
Chicken (Gallus gallus): BRCA1. 
Mutations 
Note: BRCA1 germline mutations contribute 
significantly to the development of familial/hereditary 
breast and ovarian cancer. However, each gene carries 
as many as 1000 different disease associated mutations, 
many of which are rare. These mutations are distributed 
uniformly along the entire coding region and intronic 
sequences flanking each exon. The mutations are at a 
high penetrance therefore women who carry these 
mutations have a lifetime risk of 80-90% to develop 
breast cancer. Founder mutations such as the BRCA1-
185delAG and 5382insC are found among Ashkenazi 
Jews. Larger and complex genomic rearrangements in 
the exons 21 and 22 of the BRCA1 gene, resulting in a 




Heterozygous carriers of high-risk mutations in the 
general Caucasian population have been estimated to 
be about one in 1000 for the BRCA1 gene. The lifetim  
risk of the development of hereditary breast cancer with 
the presence of BRCA1 mutations is very high. In 
addition, for sporadic breast cancer, a reduction in the 
expression of BRCA1 rather than the presence of 
mutations has been observed. The lack of a functional 
BRCA1 leads to impaired repair of DNA double strand 
breaks, cell cycle progression and transcriptional 




Mutations of the BRCA1 gene is the major cause for 
familial breast and ovarian cancer incidence. The 
lifetime risks of ovarian cancer associated with a 
BRCA1 gene mutation carrier has been estimated as 40 
to 50%. The most common mutations are frameshift 
and nonsense mutations that are predicted to cause 
premature truncation of the BRCA1 protein. In 
addition, mutations that are predicted to affect splice-
site consensus sequences as well as missense mutation 
have also been seen in ovarian cancer. Large genomic 
alterations, such as the gains in copy number of exn 
13 as well as deletion of exons in the BRCA1 gene is 
also associated with the development of ovarian cancer. 
Other cancers 
Disease 
An increased relative risk to the development of cancer 
of the colon, cervix, uterus, pancreas and prostate h s 
been suggested in BRCA1-mutation carriers. 
References 
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman 
K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A 
strong candidate for the breast and ovarian cancer 
susceptibility gene BRCA1. Science 1994;266(5182):66-71. 
Baumann P, Benson FE, West SC. Human Rad51 protein 
promotes ATP-dependent homologous pairing and strand 
transfer reactions in vitro. Cell 1996;87(4):757-766. 






Atlas Genet Cytogenet Oncol Haematol. 2008;12(3)  200 
Chapman MS, Verma IM. Transcriptional activation by BRCA1. 
Nature 1996;382(6593):678-679. 
Ruffner H, Verma IM. BRCA1 is a cell cycle-regulated nuclear 
phosphoprotein. Proc Natl Acad Sci USA 1997;94(14):7138-
7143. 
Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, 
Livingston DM, Parvin JD.  BRCA1 is a component of the RNA 
polymerase II holoenzyme. Proc Natl Acad Sci USA 
1997;94(11):5605-5610. 
Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun 
J, Livingston DM. Dynamic changes of BRCA1 subnuclear 
location and phosphorylation state are initiated by DNA 
damage. Cell 1997;90(3):425-435. 
Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, 
Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, 
Scully R. Stable interaction between the products of the 
BRCA1 and BRCA2 tumor suppressor genes in mitotic and 
meiotic cells. Mol Cell 1998;2(3):317-328. 
Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H. 
BRCA1 regulates p53-dependent gene expression. Proc Natl 
Acad Sci USA 1998;95(5):2302-2306. 
Rice JC, Massey-Brown KS, Futscher BW. Aberrant 
methylation of the BRCA1 CpG island promoter is associated 
with decreased BRCA1 mRNA in sporadic breast cancer cells. 
Oncogene 1998;17(14):1807-1812. 
Chai YL, Cui J, Shao N, Shyam E, Reddy P, Rao VN. The 
second BRCT domain of BRCA1 proteins interacts with p53 
and stimulates transcription from the p21WAF1/CIP1 promoter. 
Oncogene 1999;18(1):263-268. 
Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, Chen PL, 
Sharp ZD, Lee WH. Association of BRCA1 with the hRad50-
hMre11-p95 complex and the DNA damage response. Science 
1999;285(5428):747-750. 
Pao GM, Janknecht R, Ruffner H, Hunter T, Verma IM. 
CBP/p300 interact with and function as transcriptional 
coactivators of BRCA1. Proc Natl Acad Sci USA 
2000;97(3):1020-1025. 
Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, 
a super complex of BRCA1 associated proteins involved in the 
recognition and repair of aberrant DNA structures. Genes Dev 
2000;14:927-939. 
Atlas E, Stramwasser M, Mueller CR. A CREB site in the 
BRCA1 proximal promoter acts as a constitutive transcriptional 
element. Oncogene 2001;20(48):7110-7114. 
Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, 
Yabuki Y, Ogata H, Ohta T. The RING heterodimer BRCA1-
BARD1 is a ubiquitin ligase inactivated by a breast cancer-
derived mutation. J Biol Chem 2001;276(18):14537-14540. 
Paull TT, Cortez D, Bowers B, Elledge SJ, Gellert M. Direct 
DNA binding by BRCA1. Proc Natl Acad Sci USA 
2001;98:6086-6091. 
Fabbro M, Rodriguez JA, Baer R, Henderson BR. BARD1 
induces BRCA1 intranuclear foci formation by increasing 
RING-dependent BRCA1 nuclear import and inhibiting BRCA1 
nuclear export. J Biol Chem 2002;277(24):21315-21324. 
Jasin M. Homologous repair of DNA damage and 
tumorigenesis: the BRCA connection. Oncogene 
2002;21(58):8981-8993. 
Sobczak K, Krzyzosiak WJ. Structural determinants of BRCA1 
translational regulation. J Biol Chem 2002;277(19):17349-
17358. 
Fabbro M, Savage K, Hobson K, Deans AJ, Powell SN, 
McArthur GA, Khanna KK. BRCA1-BARD1 complexes are 
required for p53Ser-15 phosphorylation and a G1/S arrest 
following ionizing radiation-induced DNA damage. J Biol Chem 
2004;279(30):31251-31258. 
Scully R, Xie A, Nagaraju G. Molecular functions of BRCA1 in 
the DNA damage response. Cancer Biol Ther 2004;3(6):521-
527. 
Durant ST, Nickoloff JA. Good timing in the cell cycle for 
precise DNA repair by BRCA1. Cell Cycle 2005;4(9):1216-
1222. 
Boulton SJ. Cellular functions of the BRCA tumour suppressor 
proteins. Biochem Soc Trans 2006;34(Pt 5):633-645. 
Cantor SB, Andreassen PR. Assessing the link between 
BACH1 and BRCA1 in the FA pathway. Cell Cycle 
2006;5(2):164-167. 
Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in 
transcriptional regulation and cell cycle control. Oncogene 
2006;25(43):5854-5863. 
Peng M, Litman R, Jin Z, Fong G, Cantor SB. BACH1 is a DNA 
repair protein supporting BRCA1 damage response. Oncogene 
2006;25(15):2245-2253. 
Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins 
J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, 
Soucek P, King MC. Spectrum of mutations in BRCA1, 
BRCA2, CHEK2, and TP53 in families at high risk of breast 
cancer. JAMA 2006;295(12):1379-1388. 
Ferla R, Calo V, Cascio S, Rinaldi G, Badalamenti G, Carreca 
I, Surmacz E, Colucci G, Bazan V, Russo A. Founder 
mutations in BRCA1 and BRCA2 genes. Ann Oncol 2007;18 
Suppl 6:vi93-98. 
Horwitz AA, Affar el B, Heine GF, Shi Y, Parvin JD. A 
mechanism for transcriptional repression dependent on the 
BRCA1 E3 ubiquitin ligase. Proc Natl Acad Sci USA 
2007;104(16):6614-6619. 
Martin RW, Orelli BJ, Yamazoe M, Minn AJ, Takeda S, Bishop 
DK. RAD51 Up-regulation Bypasses BRCA1 Function and Is a 
Common Feature of BRCA1-Deficient Breast Tumors. Cancer 
Research 2007;67:9658-9665. 
Oldenburg RA, Meijers-Heijboer H, Cornelisse CJ, Devilee P. 
Genetic susceptibility for breast cancer: how many more genes 
to be found?. Crit Rev Oncol Hematol 2007;63(2):125-149. 
Ramus SJ, Harrington PA, Pye C, Dicioccio RA, Cox MJ, 
Garlinghouse-Jones K, Oakley-Girvan I, Jacobs IJ, Hardy RM, 
Whittemore AS, Ponder BA, Piver MS, Pharoah PD, Gayther 
SA. Contribution of BRCA1 and BRCA2 mutations to inherited 
ovarian cancer. Hum Mutat 2007;28(12):1207-1215. 
Zikan M, Pohlreich P, Stribrna J, Kleibl Z, Cibula D. Novel 
complex genomic rearrangement of the BRCA1 gene. Mutat 
Res 2007; 637 (1-2):205-208. 
This article should be referenced as such: 
Banerjee S. BRCA1 (breast cancer 1, early onset). Atlas Genet 
Cytogenet Oncol Haematol.2008;12(3):197-200.  
 
 
